CAMBRIDGE, Mass., Jan. 22, 2016 /PRNewswire/ -- Broad Institute Genomic Services has partnered with Takeda Pharmaceutical Company Limited to perform genomic analysis on patient samples from a Phase 3 clinical trial of NINLARO® (ixazomib), an oral proteasome inhibitor that was recently approved by the U.S. Food and Drug Administration (FDA), indicated in combination with lenalidomide and dexamethasone, for the treatment of patients with multiple myeloma who have received at least one prior therapy.
Data generated from the analysis are expected to expand the understanding of multiple myeloma biology and potentially identify mechanisms of sensitivity or resistance to proteasome inhibitor treatment, which will inform and improve future therapies.
The Broad Institute is a non-profit research institute aimed at advancing the understanding and treatment of disease, including through collaborations with academic and industrial partners. In addition to the institute's scientific collaborations, Broad Institute Genomic Services, launched in 2015, provides pharmaceutical companies and others access to certain specific capabilities and resources on a fee-for-service basis in connection with clinical research and clinical trials.
The Broad Genomics Platform processes hundreds of thousands of samples annually – including sequencing the equivalent of one human genome every 12 minutes. This is the first major external project announced by Broad Institute Genomic Services.
"The close relationship between the Broad Institute and Takeda provided the flexibility to design, develop, and implement next generation sequencing as a biomarker platform to accelerate genomic translational research in oncology clinical trials," said Sunita Badola, associate director, Translational Medicine at Takeda. "Broad was able to provide its expertise in sequencing methods and data generation for a variety of sample modalities in oncology."
"This pharma-academic partnership enabled the interaction of oncologists, technology specialists and genomic data analysis leaders to further understand the biology of multiple myeloma, a key component of Takeda's ongoing commitment to patients with hematological malignancies," said Andrew Dorner, vice president, Translational Medicine at Takeda.
The pivotal Phase 3 clinical trial, known as TOURMALINE-MM1, compared NINLARO combined with lenalidomide and dexamethasone to placebo plus lenalidomide and dexamethasone. The trial involved collection of tumor plasma cells from patients when they enrolled into the trial and from patients whose disease reappeared after initial response or progressed during treatment. Hundreds of these samples were profiled by RNA sequencing and DNA mutational analysis using a targeted panel interrogating 754 genes. The panel was designed by Takeda in collaboration with the Broad Institute and run through the Broad Institute's CLIA approved, CAP accredited laboratory.
"Takeda is a fantastic example of an external group leveraging the Broad Institute's capabilities to accelerate their genomic discovery," said Jane Wilkinson, senior director of project and alliance management at the Broad Institute. "Working closely with the group at Takeda allowed us to overcome unique challenges in implementing the proper regulatory elements to enable the generation of genomic data from clinical trials. We have benefitted from this relationship in the development of a high-quality system that provides the infrastructure to produce data in the type of regulated environment that is necessary for utilizing genomic data to improve therapeutic clinical trials going forward."
To learn more about Broad Institute Genomic Services, please visit genomics.broadinstitute.org.
About the Broad Institute of MIT and Harvard
The Eli and Edythe L. Broad Institute of MIT and Harvard was launched in 2004 to empower this generation of creative scientists to transform medicine. The Broad Institute seeks to describe all the molecular components of life and their connections; discover the molecular basis of major human diseases; develop effective new approaches to diagnostics and therapeutics; and disseminate discoveries, tools, methods and data openly to the entire scientific community.
Founded by MIT, Harvard and its affiliated hospitals, and the visionary Los Angeles philanthropists Eli and Edythe L. Broad, the Broad Institute includes faculty, professional staff and students from throughout the MIT and Harvard biomedical research communities and beyond, with collaborations spanning over a hundred private and public institutions in more than 40 countries worldwide. For further information about the Broad Institute, go to broadinstitute.org.
SOURCE Broad Institute of MIT and Harvard